The Patient-focused Drug Development (PFDD) program was initiated at FDA from 2012- 2017 under Congressional Mandate (PDUFA V) to more systematically obtain the patient perspective on specific diseases and their treatments. PFDD meetings provide key stakeholders an opportunity to hear the patient’s voice.
View this resource Bookmark this resource
Patient-focused drug development program
Published by IRDiRC
Regulatory AffairsEarly Access SupportPatient AdvicePatient SupportRegulatory AdvicePatient Focused Drug Development Programme